. Author manuscript; available in PMC: 2014 Jan 13.

Published in final edited form as: Invert Neurosci. 2012 May 5;12(1):37–41. doi: 10.1007/s10158-012-0135-8

Table 3.

Sensitivity of various C. elegans mutants to anthelmintics

Genotype	Drug	LC₅₀ (μg/mL)	LC₅₀ (μM)	95 % Confidence limits	Fold change^c	Result^d
N2 (wild type)	Cry5B	7.16	0.05	6.56–7.82
lev-8(ye493)^a		5.02	0.04	4.62–5.46	0.70	H
unc-50(ye494)^a		5.61	0.04	5.01–6.26	0.78	H
N2 (wild type)	Tribendimidine	51.76	114.4	45.70–58.97
bre-5(ye17)^b		9.39	20.7	8.28–10.64	0.18	H
N2 (wild type)	Levamisole	18.07	75.1	15.10–21.32
bre-5(ye17)^b		9.19	38.2	7.57–10.81	0.50	H

The LC₅₀ values along with 95 % confidence limits are shown (modified from Hu et al. 2010b)

These mutants are resistant to nAChR agonists like tribendimidine and levamisole

This mutant is resistant to Cry5B

The ratio of the LC₅₀ of the mutant to the LC₅₀ of wild-type. Fold change values <1 indicate the mutant is more sensitive to the drug than wild type (i.e., hypersusceptible)

H hypersusceptible